Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Specialties
  • Dermatology
  • Page 6
Prademagene Zamikeracel: A Breakthrough Gene Therapy for Chronic Wounds in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Posted inAllergy & Immunology Clinical Updates Dermatology Pediatrics Specialties

Prademagene Zamikeracel: A Breakthrough Gene Therapy for Chronic Wounds in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Posted by MedXY By MedXY 08/02/2025
A phase 3 trial demonstrates prademagene zamikeracel significantly accelerates healing and reduces pain in large, chronic RDEB wounds, offering a promising gene therapy with a favorable safety profile.
Read More
Dual IL-17A/F Blockade and Increased Candidiasis Risk
Posted inClinical Updates Dermatology Infectious Diseases news Specialties

Dual IL-17A/F Blockade and Increased Candidiasis Risk

Posted by MedXY By MedXY 07/31/2025
Blocking both IL-17A and IL-17F impairs neutrophil migration, reducing antifungal defense and raising candidiasis risk in patients on bimekizumab, according to in vitro evidence.
Read More
Rapid Initial Benefits of Secukinumab in Early Psoriatic Arthritis: Insights from a Treat-to-Target Randomized Trial
Posted inClinical Updates Dermatology news Specialties

Rapid Initial Benefits of Secukinumab in Early Psoriatic Arthritis: Insights from a Treat-to-Target Randomized Trial

Posted by MedXY By MedXY 07/31/2025
Early secukinumab use in newly diagnosed psoriatic arthritis delivers faster clinical improvement at 3 months compared to standard care, but this advantage diminishes by 6 months and beyond.
Read More
JAK Inhibitors and Venous Thromboembolism in Atopic Dermatitis: Clinical Risks and Practice Implications
Posted inClinical Updates Dermatology news Specialties

JAK Inhibitors and Venous Thromboembolism in Atopic Dermatitis: Clinical Risks and Practice Implications

Posted by MedXY By MedXY 07/30/2025
JAK inhibitors significantly increase the risk of venous thromboembolism compared to dupilumab and methotrexate in atopic dermatitis, underscoring the need for individualized risk stratification.
Read More
FDA Fast-Tracks Rezpegaldesleukin for Severe Alopecia Areata: Promise for a Challenging Disease
Posted inClinical Updates Dermatology news Specialties

FDA Fast-Tracks Rezpegaldesleukin for Severe Alopecia Areata: Promise for a Challenging Disease

Posted by MedXY By MedXY 07/30/2025
The FDA has granted Fast Track status to rezpegaldesleukin (REZPEG), a novel biologic targeting regulatory T cells, for severe-to-very severe alopecia areata in patients aged ≥12 years. Phase 2b trial results are anticipated in December 2025.
Read More
JAK Inhibitors and Thromboembolic Risk in Atopic Dermatitis: A Comparative Safety Signal
Posted inClinical Updates Dermatology Specialties

JAK Inhibitors and Thromboembolic Risk in Atopic Dermatitis: A Comparative Safety Signal

Posted by MedXY By MedXY 07/29/2025
A large real-world cohort study finds JAK inhibitors increase risk of venous thromboembolism versus dupilumab and methotrexate in atopic dermatitis, highlighting the need for individualized therapy.
Read More
Scrotal Eczema: Understanding, Treating, and Preventing This Common Yet Distressing Condition
Posted inDermatology news

Scrotal Eczema: Understanding, Treating, and Preventing This Common Yet Distressing Condition

Posted by MedXY By MedXY 07/26/2025
Scrotal eczema causes significant discomfort but can be effectively managed with the right care. Learn about causes, treatments, and tips to prevent flare-ups.
Read More
Hair Transplantation: Is It a Permanent Solution for Hair Loss?
Posted inDermatology news Plastic Surgery

Hair Transplantation: Is It a Permanent Solution for Hair Loss?

Posted by MedXY By MedXY 07/26/2025
Exploring whether hair transplantation truly offers a permanent fix for hair loss, this article examines scientific evidence, common myths, and practical advice for those considering the procedure.
Read More
Can Hair Transplants Offer a Permanent Solution to Balding?
Posted inDermatology news

Can Hair Transplants Offer a Permanent Solution to Balding?

Posted by MedXY By MedXY 07/26/2025
Explore whether hair transplants provide a lasting solution to baldness, along with insights into prevention and treatment options.
Read More

Posts pagination

Previous page 1 … 4 5 6
  • Why Time Below Range Is a Poor Standalone Predictor of Severe Hypoglycemia: Evidence from Six Clinical Trials
  • LOXL2 Inhibition: A New Frontier in Treating LMNA-Related Dilated Cardiomyopathy
  • The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation
  • Transcatheter Edge-to-Edge Repair Superior to Medical Therapy in Atrial Functional Mitral Regurgitation: Evidence from Real-World Registries
  • Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in